Algernon Pharmaceuticals has now enrolled 50% of patients for its Ifenprodil IPF/Chronic Cough study and announces that Ifenprodil has reduced Interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial.
Algernon Pharmaceuticals (CSE: AGN – OTCQB: BTHCF) – CEO Christopher Moreau of Algernon Pharmaceuticals joins Steve Darling from Proactive to discuss the announcement that Ifenprodil has reduced Interleukin 6 with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial. This is key information for the ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough taking place in Australia and New Zealand.
Algernon Pharmaceuticals also reports the Company has reached 50% of its enrollment target for this Phase 2 study of Ifenprodil. The 20-patient proof-of-concept trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients and associated chronic cough.